Related Experiment Video
Updated: Oct 4, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
[Dermatology - Latest developments in targeted therapies for atopic dermatitis, alopecia areata and chronic
Aurélie Piletta-Zanin1, Aurélie Hsieh2, Michael Mühlstädt2
1Faculté de médecine, Université de Genève, 1211 Genève 4.
Abstract:
In recent years, a lot of targeted therapies have appeared on the market. The huge choice and rapid development make it sometimes difficult to stay up to date. This article reviews the latest therapies in the field of atopic dermatitis, alopecia areata and chronic spontaneous urticaria. Anti-IL-4 and anti-IL-13 antibodies and, more recently, JAK inhibitors have been proven to be effective for moderate to severe atopic dermatitis. JAK inhibitors seem promising for the treatment of severe alopecia areata. Ligelizumab and nemoli zumab will provide therapeutical options for chronic spontaneous urticaria and prurigo respectively. These breakthroughs will improve the quality of life of people suffering from invalidating dermatitis, at a certain price.
Insights
New targeted therapies offer hope for atopic dermatitis, alopecia areata, and chronic spontaneous urticaria. Advanced treatments like JAK inhibitors and specific antibodies are improving patient quality of life.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- The rapid development of targeted therapies presents challenges in staying current.
- Atopic dermatitis, alopecia areata, and chronic spontaneous urticaria are significant dermatological conditions.
Purpose of the Study:
- To review the latest advancements in targeted therapies for atopic dermatitis, alopecia areata, and chronic spontaneous urticaria.
- To highlight the efficacy and potential of novel treatment options.
Main Methods:
- Literature review of recent clinical studies and therapeutic developments.
- Analysis of targeted therapies including monoclonal antibodies and small molecule inhibitors.
Main Results:
- Anti-interleukin-4 (IL-4) and anti-interleukin-13 (IL-13) antibodies, along with Janus kinase (JAK) inhibitors, show efficacy in moderate to severe atopic dermatitis.
- JAK inhibitors demonstrate promise for severe alopecia areata.
- Ligelizumab and nemolizumab present new therapeutic avenues for chronic spontaneous urticaria and prurigo, respectively.
Conclusions:
- Recent breakthroughs in targeted therapies are significantly improving treatment options for debilitating skin conditions.
- These novel treatments offer enhanced quality of life for patients, though cost remains a consideration.
Related Concept Videos
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

